Floatz logo

Zactima

Hereditary Leiomyomatosis

National Cancer Institute (NCI)Phase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Hereditary Leiomyomatosis cohort.

Asset / SponsorPhaseRating
Atezolizumab
National Cancer Institute (NCI)
Phase 2CCC
DENTALFLUORO
National Cancer Institute (NCI)
Phase 2CCC
Pamiparib
Jonsson Comprehensive Cancer Center
Phase 2CCC
Metformin
National Cancer Institute (NCI)
Phase 1/2CCC
Lactate
University of Texas Southwestern Medical Center
N/AD

View all 9 →

Same molecule, other indications

Zactima is also rated in:

metastatic neoplasmDormant
B
Indicative ·
63 / 100
View asset →
gliosarcomaDormant
B
Indicative ·
63 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →